Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol in fatty liver disease
NCT04761848Phase 2Withdrawn
- Sponsor
- Sadat City University
- Start
- Feb 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cilostazol in non-alcoholic fatty liver disease (NAFLD), sponsored by Sadat City University. Planned start Feb 2021; status: withdrawn.
02
Drugs
cilostazol
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04761848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761848.